Stockscreener 앱 받기
1.55
2.52%
-0.04
시간 외 거래:
1.56
0.01
+0.65%
Biorestorative Therapies Inc 주식(BRTX)의 최신 뉴스
Transcript : BioRestorative Therapies, Inc.Special Call - MarketScreener
BioRestorative CEO Reveals New BRTX-100 Clinical Data and Growth Strategy: Key Updates You Can't Miss Today - Stock Titan
Stock Buyback Plan Declared by Biorestorative Therapies (NASDAQ:BRTX) - Defense World
BioRestorative Therapies (BRTX) Initiates $2 Million Stock Buyba - GuruFocus
BioRestorative Announces Share Repurchase Program - Ortho Spine News
BioRestorative Therapies (BRTX) Initiates $2 Million Stock Buyback Program | BRTX Stock News - GuruFocus
BioRestorative Therapies' Board Of Directors Authorizes Repurchase Of Up To $2 Mln Of Common Stock - Nasdaq
BioRestorative Therapies, Inc. Announces $2 Million Stock Repurchase Program to Enhance Shareholder Value - Nasdaq
BioRestorative CEO Signals Stock Undervalued, Announces $2M Share Repurchase Plan - Stock Titan
BioRestorative Therapies (BRTX) Reports Promising Phase 2 Trial - GuruFocus
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease - Ortho Spine News
Anchoring Your Portfolio: Is BRTX Stock a Safe Harbor? - investchronicle.com
BioRestorative Reports Promising Phase 2 Trial Results - TipRanks
BioRestorative Therapies Says BRTX-100 Improved Function in Phase 2 Chronic Lumbar Disc Disease Trial - marketscreener.com
BioRestorative reports positive data from BRTX-100 stem cell therapy trial - Investing.com Nigeria
BioRestorative Reports Compelling Preliminary Data For FDA-Fast-Tracked BRTX-100 - marketscreener.com
BioRestorative Therapies, Inc. Reports Promising Phase 2 Clinical Trial Results for BRTX-100 at ISSCR 2025 Annual Meeting - Nasdaq
Breakthrough Stem Cell Therapy BRTX-100 Achieves 74% Success Rate in Chronic Back Pain Trial - Stock Titan
Citadel Advisors LLC Buys New Stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading 0.3% Higher – Still a Buy? - Defense World
Stocks in play: ATCO Ltd. - The Globe and Mail
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team - Barchart.com
BRTX Appoints Sandy Lipkins for Strategic Expansion | BRTX Stock News - GuruFocus
30-Year Regenerative Medicine Pioneer Joins BioRestorative to Lead Global Commercialization Strategy - Stock Titan
BioRestorative Therapies (NASDAQ:BRTX) Shares Up 0.3% – Should You Buy? - Defense World
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 - The Globe and Mail
BioRestorative Therapies to Present New Preliminary Clinical Data for BRTX-100 at ISSCR 2025 Annual Meeting - Nasdaq
Major Phase 2 Clinical Trial Update: BRTX-100 Stem Cell Therapy Shows New Safety Data in 30 Back Pain Patients - Stock Titan
BioRestorative Therapies Announces Closing of $23 Million Public Offering - The Globe and Mail
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Down 3.6% – Should You Sell? - Defense World
What is Roth Capital’s Estimate for BRTX Q2 Earnings? - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
BioRestorative Therapies’ Earnings Call: Progress Amid Challenges - TipRanks
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates - MSN
BioRestorative Therapies Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: BioRestorative Therapies Q1 2025 sees widened losses - Investing.com Nigeria
BioRestorative Therapies Reports Q1 2025 Results and Updates - TipRanks
BIORESTORATIVE THERAPIES Earnings Results: $BRTX Reports Quarterly Earnings - Nasdaq
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update - Ortho Spine News
BioRestorative's Spine Treatment Gets FDA Fast Track After Positive 52-Week Trial Data - Stock Titan
BioRestorative Therapies (BRTX) Reports Positive Initial Results in Phase 2 Trial | BRTX Stock News - GuruFocus
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data - Ortho Spine News
BioRestorative Therapies, Inc. Announces Positive Preliminary Data from Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease at ISCT 2025 Annual Meeting - Nasdaq
BioRestorative Therapies (BRTX) to Release Quarterly Earnings on Wednesday - Defense World
BioRestorative Therapies Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 - The Manila Times
BioRestorative Therapies, Inc. to Release First Quarter 2025 Financial Results on May 14, 2025 - Nasdaq
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 - The Manila Times
BioRestorative To Present A BRTX-100 Clinical Update At ISCT 2025 - Barchart.com
Reviewing BioRestorative Therapies (OTCMKTS:BRTX) and Silence Therapeutics (OTCMKTS:SLNCF) - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Down 2.3% – Here’s Why - Defense World
0.68%
0.50%
자본화:
|
볼륨(24시간):